The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Progress in the categorization and treatment of LR-MDS
Valeria Santini, MD, University of Florence, Florence, Italy, discusses the categorization system of lower-risk myelodysplastic syndromes (LR-MDS), stating that IPSS-M allows the best patient selection and therapy optimization. She mentions several agents that could treat LR-MDS, including erythropoiesis-stimulating agents (ESAs) and luspatercept, with a particular emphasis on the early use of lenalidomide to delay transfusion dependence. Additionally, Prof. Santini mentions the newly approved imetelstat, which can induce transfusion independence for longer than a year. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
